Targeted Therapies for Autosomal Dominant Polycystic Kidney Disease.
CONCLUSION: Many compounds are currently in clinical trial for ADPKD, yet to date, none are FDA-approved for treating this disease. Patients could benefit from efficacious pharmacotherapy, especially if it can be kidney-targeted, and intensive efforts continue to be focused on this goal.
PMID: 29737248 [PubMed - as supplied by publisher]
Source: Current Medicinal Chemistry - Category: Chemistry Authors: Stayner C, Brooke DG, Bates M, Eccles MR Tags: Curr Med Chem Source Type: research
More News: Calcium | Chemistry | Clinical Trials | Dialysis | Genetics | Hemodialysis | Kidney Transplant | Kidney Transplantation | Pathology | Polycystic Kidney Disease | Toxicology | Transplants | Urology & Nephrology